The relationship of hyperlipidemia with maternal and neonatal outcomes in pregnancy: A cross-sectional study by Hajar Sharami, Seyedeh et al.
International Journal of Reproductive BioMedicine
Volume 17, Issue no. 10, https://doi.org/10.18502/ijrm.v17i10.5294
Production and Hosting by Knowledge E
Research Article
The relationship of hyperlipidemia with
maternal and neonatal outcomes in
pregnancy: A cross-sectional study
SeyedehHajar Sharami1 M.D., Zahra Abbasi Ranjbar1 M.D., Fatemeh Alizadeh1
M.D., Ehsan Kazemnejad2 Ph.D.
1Reproductive Health Research Center, Department of Obstetrics and Gynecology,
Al-zahra Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
2Social Determinants of Health Research Center, Guilan University of Medical Sciences, Rasht,
Iran.
Abstract
Background: Concentrations of plasma lipids levels during pregnancy clearly
increases. According to some studies, dyslipidemia is effective in the incidence of
preeclampsia and insulin resistance.
Objective: This study aimed to examine the relationship between hyperlipidemia and
maternal and neonatal outcomes in pregnant women.
Materials and Methods: This is a cross-sectional study which was conducted on two
groups of pregnant women with hyperlipidemia and normal ones to assess maternal
and neonatal outcomes. Maternal data including gestational age, mother’s age, body
mass index, and maternal weight gain during pregnancy, gestational diabetes mellitus,
preeclampsia, cholestasis, and delivery method. Also, birth weight and Apgar score
were gathered as the neonatal outcomes.
Results: The results showed that the prevalence of abnormal lipid parameters
increased with increasing gestational age. In pregnant women with dyslipidemia in
combination with increased triglyceride, cholesterol and Low-density lipoprotein, and
decreased High-density lipoprotein, the incidence rates of gestational diabetes (p <
0.001), preeclampsia (p < 0.001), cholestasis (p = 0.041), fetal growth retardation (p <
0.001), and macrosomia (p < 0.001) were statistically higher.
Conclusion: Dyslipidemia was associated with some adverse effects of pregnancy
and harmful fetal outcomes. Therefore, it seems that adding laboratory assessment
of lipid profiles before and during pregnancy can be effective in early diagnosis of
dyslipidemia.
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1. Introduction
In the first trimester of pregnancy, an increase
in serum lipids due to increased lipogenesis and
lipolysis suppression can occur. Besides, increased
lipolysis and increased levels of fatty acids can
be expected at the second trimester of preg-
nancy. Maternal energy metabolism in the middle
of pregnancy is directed toward lipolysis, which
leads to an increase in the circulating levels of
fatty acids. These changes in lipid metabolism
indicate a physiological adaptation of the mother’s
body that transforms glucose metabolism into lipid
metabolism to provide it for fetal development (1).
Studies have shown that lipid abnormalities are
predictive of insulin resistance (2, 3). Gestational
diabetes mellitus (GDM) can affect up to 22% of
all pregnancies (1). Gestational diabetes is any type
of disorder in glucose during pregnancy which
is diagnosed for the first time. The diagnosis is
confirmed by administering 75 g glucose and the
existence of >= 1 following glucose levels: fasting
blood glucose> 92, after 1 hr> 180, and after 2 hr>
153 (1). In women with GDM, physiological changes
in insulin and lipid profiles are more severe and
may lead to metabolic disorders in this period (4).
Few studies have ever assessed the role of lipid
profiles in predicting GDM and the results were
contradictory (1, 5). Obesity is one of the main risk
factors for both insulin resistance and dyslipidemia
during pregnancy, which can lead to GDM (6).
Dyslipidemia during pregnancy can also be
associated with neonatal outcomes (7). Moreover,
Hypertriglyceridemia in obese pregnant women
can have negative effects on maternal outcomes
and in the long period it can lead to metabolic
syndrome in children (8). Disturbances in mater-
nal triglyceride levels during pregnancy and non-
esterified fatty acid metabolism are in relation to
the fetal overgrowth (9). Recent studies have shown
that there was a positive correlation between
maternal triglyceride levels and Large for Gesta-
tional Age (LGA), which was independent of the
maternal glycemic status (10). Also, it has been
shown that the concentration of triglyceride was
an independent risk factor for macrosomia (11,
12). However, the relationship between maternal
triglyceride level and birth weight is still a contro-
versial issue.
Despite studies in this area, it is still unclear
how dyslipidemia can be a potential risk factor
for insulin resistance during pregnancy. Regarding
this issue and also considering that early diag-
nosis of these disorders can be highly effective
in reducing maternal and neonatal complications,
and the hospital is the tertiary referral hospital
and all high-risk patients were referred from Guilan
province; this study aimed to examine the relation-
ship between hyperlipidemia and maternal (GDM,
preeclampsia, and cholestasis, etc.) and neonatal
outcomes (macrosomia, preterm labor, LGA, small
for Gestational Age (SGA), etc.)
2. Materials and Methods
2.1. Population and settings
This study is an analytical cross-sectional study
which was conducted on the mothers who were
eventually referred to the Al-Zahra hospital, Rasht,
Iran in 2016-2017. Singleton pregnancies at 28-
42 gestational wk (3rd trimester) were included
in this study. Mothers with multiple pregnan-
cies, having diabetes type 1 or 2, chromosomal,
hereditary metabolic and thyroid diseases before
pregnancy, pregnancy with assisted reproductive
technologies, who had no glucose tolerance test-
ing during pregnancy, were not included in this
study.
Data were collected using a checklist including
demographic and laboratory results. Gestational
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age at the time of delivery was assessed based
on the last menstrual period and the ultrasound
of the first trimester. Maternal age, weight, and
height were recorded and maternal Body mass
index (BMI) was calculated based on dividing pre-
pregnancy or first-trimester weight (kg) to squared
height (m).
The family history of diabetes, the level of
education, and the deliverymethod (natural vaginal
delivery or cesarean section) were also recorded.
For assessing the fat profile analysis, Hitachi Auto
Analyzer, and pars test cholesterol, triglyceride,
and high-density lipoprotein (HDL) kits were used.
Hyperlipidemia is defined as the presence of one
of the following items including serum cholesterol
concentration > 200 mg/dL, triglyceride ≥ 150
mg/dL, HDL-C≤ 45mg/dL, and low-density lipopro-
tein (LDL-C) ≥ 130 mg/dL.
After identifying maternal hyperlipidemia, preg-
nant women were divided into two groups - with
and without hyperlipidemia. In order to identify
GDM, initial screening by measuring plasma or
serum glucose concentration 1 hr after a 50 gr oral
glucose load (glucose challenge test (GCT)) and a
diagnostic oral glucose tolerance test (OGTT) in the
subset of women exceeding the glucose threshold
value on GCT. Women were diagnosed as having
gestational diabetes if their blood glucose was >
95mg/dl after an overnight fast and was>180,155
and 140 mg/dl after 1, 2, and 3 hr after ingest-
ing a 100gr glucose solution, respectively (13).
Preeclampsiawas defined as a specific pregnancy-
induced disorder characterized with hypertension
(systolic blood pressure ≥ 140 mmHg and/or dias-
tolic blood pressure ≥ 90 mmHg) and significant
proteinuria (urine protein ≥ 300 mg/24 hr or
positive results in random urine protein tests) in
previously normotensive women on or after 20
wk gestational age. Cholestasis was determined
based on clinical manifestations such as itching
and elevated liver enzyme. Biliary obstruction
was ruled out by ultrasound. The neonate’s birth
weight and the first- and fifth-min Apgar scores
were measured. Based on the birth weight, those
under 2,500 gr were considered low birth weight
(LBW), between 2, 500 and 4,000 gr were normal,
and those > 4,000 gr were considered micro-
somes.
2.2. Sample size
According to the formula, 539 pregnant women
were assessed. The sample size needed to deter-
mine the relationship between hyperlipidemia and
somematernal and neonatal outcomes in pregnant
women with 95% confidence and 80% power
based on the results of Jin et al. (14).
1 − 𝛼 = 0.95 ⇒ 𝑍1−𝛼/2 = 𝑍0.975 = 1.96
1 − 𝛽 = 0.9 ⇒ 𝑍1−𝛽 = 𝑍0.9 = 0.84
Odds ratio = 1.5 preeclampsia P = 10%
𝑛=
(𝑍1−𝛼/2 + 𝑍1−𝛽)2
𝑃 (1−𝑃 ).(ln oddsRatio)2




This study was approved by the ethics commit-
tee of Guilan University of Medical Sciences, Rasht,
Iran (Code: IR GUMS.REC.1396.33) and informed
consent form was signed by all participants.
2.4. Statistical analysis
Data were analyzed using SPSS (Statistical Pack-
age for the Social Sciences, version 21.0, SPSS Inc,
Chicago, Illinois, USA). The relationship between
hyperlipidemia during pregnancy and GDM and
other outcomes were assessed before and after
the adjustment of the effects of confounding fac-
tors. Chi-square test was used to compare the
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frequency of maternal outcomes regarding dys-
lipidemia status. If the test was not valid, Fisher’s
exact test was used. To compare quantitative
normal distributed variables, the independent t-
test was used and the Mann-Whitney U test was
used for non-normal distributed variables. To com-
pare the relationship between hyperlipidemia and
maternal and neonatal outcomes with controls,
the logistic regression test and the odds ratio
were used. P-value < 0.05 indicated statistical
significance.
3. Results
Totally, 539 pregnant women were participated
in this study. The mean age of participants was
30.07 ± 6.15 yr. In terms of educational level, the
majority of the women were < diploma (45.1%).
The majority of mothers had no history of GDM
(85.2%) (Table I). The mean BMI was 27.53 ±
6.11 kg/m2, and the mean weight gain during the
pregnancy was 13.26 ± 10.55 kg. The mean of
other baseline characteristics are shown in Table
II.
According to our results, 364 women (67.5%)
had hypertriglyceridemia, 294 (54.5%) had hyper-
cholesterolemia, 152 (28.2%) had abnormal HDL,
and 174 (32.3%) had abnormal LDL. Totally, 448
participants (83.1%) had dyslipidemia.
In this study, 31% cases had GDM, 29.9% had
preeclampsia, 7.3% had cholestasis in pregnancy,
and 16.1% had newborns weighing < 2,500 gr at
birth. In terms of delivery, 69.7% had a cesarean
section and 30.3% had a vaginal delivery. Chi-
square test showed a significant relation between
groups regarding the frequency of GDM (p <
0.001), preeclampsia (p < 0.001), cholestasis (p =
0.041), birth weight (p < 0.001), delivery type (p
< 0.001), and FGR (p < 0.00). GDM was 35.7%
in women with dyslipidemia and 7.7% in healthy
women; 34.2% of women with dyslipidemia and
8.8% of healthy women had preeclampsia. Mann-
Whitney U test showed that the gestational age
at delivery was 37.33 ± 2.13 in patients and
38.04 ± 1.85 in normal people, and this differ-
ence was statistically significant (p < 0.0001).
Birth weight in the dyslipidemia group was 3151.41
± 743.76 and in the non-affected group was
3195.27 ± 440.83, which was not statistically sig-
nificant (p = 0.861). Apgar scores were statistically
significant in the first minute (p < 0.001) and
in the fifth minute (p < 0.001), and the new-
borns of dyslipidemic mothers had lower Apgar
scores than the infants of healthy mothers (Table
III).
There was no significant relation between early
and late preterm labor (p = 0.006). Compar-
ing patients with early preterm labor showed
a significant relation in terms of hypertriglyc-
eridemia (p = 0.027), hypercholesterolemia (p =
0.002), and abnormal LDL (p = 0.0007). Fur-
thermore, late preterm labor showed a signifi-
cant relation in terms of hypertriglyceridemia (p
= 0.001), hypercholesterolemia (p = 0.001), and
abnormal LDL (p = 0.001). The rate of macro-
somia was different in terms of hypertriglyc-
eridemia (p = 0.001), hypercholesterolemia (p =
0.001), and hyperlipidemia (p = 0.001) (Table
IV).
Multiple logistic regression analysis was used
to analyze the relationship between dyslipidemia
and GDM after adjusting the effects of individ-
ual variables and disease records. Dyslipidemia
increased 4.1 folds the chance of a pregnancy-
induced GDM (Odds ratio= 4.1 95% CI OR: 1.8-
9.5). In addition to dyslipidemia, the maternal
age (p = 0.001, OR: 1.1), maternal education (p
= 0.01, OR = 0.679), BMI (p = 0.001, OR = 1.1),
and also the history of GDM in the previous
pregnancy (p = 0.011, OR = 5.6) had a significant
relationship with GDM. Among these variables,
only maternal education had a protective effect
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(protecting odds ratio < 1) and others were risk
factors. Results showed that by modulating the
effects of demographic and confounding variables,
dyslipidemia was considered as a factor associated
with preeclampsia (p = 0.0001) (odd = 4.1 95% CI
OR = 1.9-8.8). In addition to hyperlipidemia, the
maternal age (p = 0.002, OR = 1.05) and BMI (p
= 0.005, OR = 1.05) had a risk factor effect on
preeclampsia. Results showed that dyslipidemia
has not been considered as a factor associated
with the symptoms of cholestasis in pregnancy
by modulating the effects of demographic and
confounding variables (p = 0.07) (odd = 3.7 95% CI
OR = 0.889-15.9).
However, the history of diabetes (p = 0.02, OR
= 3.9) had a risk factor effect for the symptoms
of cholestasis. Based on the results of the final
model, logistic regression showed dyslipidemia as
a factor associated with positive FGR by modulat-
ing the effects of demographic and confounding
variables (p = 0.003) (odd = 4.8 95% CI OR =
1.69-13.39). Also, educational level (p = 0.05, OR
= 1.4) had a risk factor effect on positive FGR
(Borderline Significance). Based on the results of
the final model, logistic regression of dyslipidemia
has not been considered as a factor related to
cesarean delivery by modulating the effects of
demographic and confounding variables (p = 0.081)
(odd = 1.56 95% CI OR = 0.946-2.58). However,
maternal age (p = 0.001, OR = 1.12), BMI (p = 0.009,
OR = 1.05) had a risk factor effect on cesarean
delivery.
Table I. Frequency distribution of demographic characteristics (n = 539)
Variables N (%)
Maternal age (yr)




> 35 111 (20.6)
History of GDM in previous pregnancies 80 (14.8)
Diabetes inheritance in mother or father 156 (29.1)
BMI
< 18.5 24 (4.5)
18.5-24.99 161 (29.9)
25-29.99 202 (37.5)
≥ 30 152 (28.2)
LDL
> 150 174 (32.3)
< 150 365 (67.7)
HDL
> 50 152 (28.2)
< 50 387 (71.8)
GDM: Gestational diabetes mellitus; BMI: Body mass index; HDL: High-density lipoprotein; LDL: Low-density lipoprotein
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Table II. The mean of baseline characteristics
Variables
Maternal weight before or during the first trimester 71.14 ± 14.63
Height 161.00 ± 6.86
Triglyceride 218.61 ± 106.52
Cholesterol 217.50 ± 60.12
HDL 53.15 ± 11.72
LDL 123.21 ± 48.31




< 18.5 15 (3.3) 9 (9.9)
18.5-24.99 126 (28.1) 35 (38.5)
25-29.99 166 (37.1) 36 (39.6)
≥ 30 141 (31.5) 11 (12.1)
0.001*
GDM 160 (35.7) 7 (7.7) 0.001*
Preeclampsia 153 (34.2) 8 (8.8) 0.001*
Cholestasis 37 (8.3) 2 (2.2) 0.041*
Birth weight
< 2500 79 (17.6) 8 (8.8)
2500-4000 319 (71.2) 83 (91.2)
> 4000 50 (11.2) 0 (0.0)
0.001*
Delivery type
NVD 121 (27.0) 42 (46.7)
C/S 327 (73.0) 48 (53.3)
0.001*
FGR 80 (17.9) 4 (4.4) 0.001*
1 min Apgar score
< 7 42 (9.4) 2 (2.2)
≥ 7 406 (90.6) 89 (97.8)
0.023*
5 min Apgar score
< 7 5 (1.1) 0 (0.0)
≥ 7 443 (98.9) 91 (100.0)
0.311*
Gestational age (wk) 37.35 ± 2.13 38.04 ± 1.85 0001**
Birth weight (gr) 3151.41 ± 743.76 3195.27 ± 440.83 0.861**
1 min Apgar score 7.83 ± 1.04 8.26 ± 0.85 0.001**
5 min Apgar score 8.94 ± 0.84 9.30 ± 0.61 0.001**
Data presented as n (%)
GDM: Gestational diabetes mellitus; NVD: Normal vaginal delivery C/S: Cesarean section; FGR: Fetal uterine growth retardation
*Chi-square test; **Mann-Whitney U test: Data presented as mean ± SD
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Table IV. Frequency distribution of preterm labor and macrosomia based on maternal lipid profile
Early preterm labor Late preterm labor Macrosomia n (%)
GA ≥ 34 week GA < 34 week GA ≥ 37 week GA < 37 week
No Yes
Hypertriglyceridemia 339 (93.1) 25 (6.9) 269 (73.9) 95 (26.1) 47 (12.9) 317(87.1)
p-value 0.027** 0.001* 0.001**
Hypercholesterolemia 270 (91.8) 24 (8.2) 215 (73.1) 79 (26.9) 251 (85.4) 43 (14.6)
p-value 0.002* 0.001* 0.001*
Abnormal HDL 144 (94.7) 8 (5.3) 124 (81.6) 28 (18.4) 143 (94.1) 9 (5.9)
p-value 0.947** 0.246* 0.092
Abnormal LDL 158 (90.8) 16 (9.2) 119 (68.4) 55 (31.6) 152 (87.4) 22 (12.6)
p-value 0.007* 0.001* 0.063*
Hyperlipidemia 421 (94.0) 27 (6.0) 344 (76.8) 104 (23.2) 8398 (8.8) 50 (11.2)
p-value 0.140** 0.06 0.001**
Data presented as n(%)
*Chi-square test; **Fisher’s Exact test
HDL: High-density lipoprotein; LDL: Low-density lipoprotein; GA: Gestational age
4. Discussion
In this study, the relationship between hyper-
lipidemia and GDM and other maternal and child-
related outcomes showed that the higher the
gestational age, the greater the incidence of
lipid parameters. There was a significant rela-
tion between dyslipidemia with the incidence
of GDM, preeclampsia, cholestasis in pregnancy,
and macrosomia. Jin and colleagues mentioned
that the mean age of mothers and the mean
weight gain during pregnancy were similar to
the current study, and P-BMI and educational
level were different (14). Also, in the study of Li
and others, the mean age of mothers and P-
BMI were similar to this study and the level of
education and family history of diabetes were
different (3). Given that the mean BMI of the
current populationwaswithin the overweight range
(25-29.9), the overall weight gain in this group
was higher than the expected weight gain (7.5-
11). Lower levels of education can lead to high
levels of obesity and higher BMI by creating
cultural, socioeconomic, and lifestyle differences,
and excessive consumption of high-calorie foods.
According to the classification and lipid profile,
83.1% (448) had dyslipidemia. Two constant mani-
festations of lipid metabolism changes in a preg-
nant mother that occurs normally during pregnancy
are lipid accumulation in the maternal tissues and
the occurrence of hyperlipidemia. Fat accumulation
at the beginning of pregnancy with hyperphagia
can also increase lipogenesis (15). Hyperlipidemia
during pregnancy is a physiological phenomenon
which occurs as a result of increased insulin
resistance and the synthesis of lipoproteins and
lipolysis in adipose tissue, in order to provide fats
as a source of energy for the development of
the fetus (16). The majority of pregnant women
commonly show an increase in triglycerides in
the third trimester, an increase in HDL in the
second half of pregnancy, and a progression of
IDL and LDL during pregnancy (1). In the study
of Jin and colleagues, the presence of GDM
(7.6%), preeclampsia (1.5%), and SGA (71.3%) were
different from this study, and the occurrence of
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macrosomia, gestational age, and birth weight
were consistent.(14) Schaefer and co-worker found
higher frequency rates of GDM (76%) and macro-
somia (18.9%) (8). In the study of Wang and co-
worker, lower frequency of GDM (20.2%) was
noted (17). However, similar gestational age and
birth weight were noted by Li and co-worker
(11). Considering that this study was conducted
at the referral hospital of the capital of Guilan
province, different results compared with previous
investigations regarding GDM and preeclampsia
may be caused by referring high-risk pregnan-
cies to the center. Although, previous investiga-
tions did not assess perinatal care, delivery type,
and Apgar scores, in this study, 98.5% of the
patients had perinatal care that indicated appro-
priate culture and awareness. According to the
expectations, cesarean section was more than
NVD. One significant reason was the repeated
cesarean delivery and the lack of vaginal birth
after cesarean section (18). Also, an increased
inability to initiate labor and subsequently induc-
tion by oxytocin and cesarean section are more
common in people with abnormal weight (19), and
it decreases the likelihood of successful vaginal
birth after cesarean section in women (18). The
frequency of GDM and preeclampsia were statis-
tically significant in women with dyslipidemia and
healthy ones. Also, higher frequencies were noted
in terms of cholestasis, LBW, and cesarean section
in women with dyslipidemia. In the study of Jin
and colleagues, there was a significant relation-
ship between dyslipidemia and an increased risk
of GDM, preeclampsia, and macrosomia (14). In
the study of Liu and colleagues and Wang and
colleagues, there was a significant relationship
between dyslipidemia and GDM (11, 17). In preg-
nant women with GDM, the incidence of insulin
resistance syndrome (metabolic syndrome) was
also high. Pregnant women with diabetes mellitus
had higher rates of central obesity, glucose levels,
insulin, triglycerides, total cholesterol, and LDL
compared to the control group. It was also associ-
ated with GDM with early onset of atherosclerosis
(20). Endothelial dysfunction is an early onset sign
of atherosclerosis which usually occurs shortly
after the delivery in women with the history of
GDM. Therefore, generally, women with diabetes
mellitus are not only at risk for type 2 diabetes
but also at an increased risk of cardiovascular
complications associated with abnormal serum
fat and hypertension and abdominal obesity (21).
The association of dyslipidemia with cholestasis
can be explained by the theoretical description
provided on reducing the activity of FXR and TGR5
acid receptors, although the actual mechanism
needs to be further investigated (14). Consider-
ing hyperlipidemia as an oxidative suppressant
stimulus and the inflammation associated with
the incidence of pregnancy complications and its
harmful effects such as preeclampsia, diabetes,
and LGA (22), the occurrence of preterm labor
can be justified. Although the relationship between
maternal dyslipidemia and preterm delivery is not
consistent and this relationship has not been
reported in any systematic reviews and meta-
analysis.
4.1. Limitation
This study had some limitations but the inves-
tigators considered them to eliminate as far as
possible. Weight gain before and during pregnancy
was self-reported and may be biased. In this study,
other confounding factors were not assessed, for
example, receiving adequate or excessive diet
during pregnancy and sufficient physical activity
during pregnancy, which may have an effect on
the incidence of dyslipidemia. Therefore, it seems
that more studies are needed to investigate the
relationship between the mother’s lifestyle and the
incidence of dyslipidemia during pregnancy.
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5. Conclusion
According to the results of the present study, it
seems that adding laboratory assessment of lipid
profiles before and during pregnancy can be effec-
tive in early diagnosis of dyslipidemia. Considering
that most drugs used to treat hyperlipidemia during
pregnancy are in the C or X groups, treatment can
be related to changing the lifestyle by increased
physical activity, controlling calorie intake, and
timely treatment of disorders such as diabetes and
hypertension.
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